Vicky Makker, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses 2 agents, lenvatinib and pembrolizumab, in patients with endometrial cancers.
Vicky Makker, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses 2 agents, lenvatinib (Lenvima) and pembrolizumab (Keytruda), in patients with endometrial cancers.
While lenvatinib has previously been approved for the treatment of radioactive iodinerefractory differentiated thyroid cancer, as well as in advanced renal cell carcinoma in combination with everolimus (Afinitor), this agent has shown a modest response rate of 14% in patients with heavily pretreated endometrial cancer.
Peritoneal RFS May Be a Stronger Predictor of OS in CRC Peritoneal Metastasis
March 27th 2024In an interview with Targeted Oncology, Muhammad Talha Waheed, MBBS, discussed research on the reliability of using recurrence-free survival as an efficacy end point for trials evaluating patients with colorectal cancer peritoneal metastasis.
Read More